Search

Displaying results 3081 - 3090 of 8517 in total
  1. Drug

    Depemokimab

    go.drugbank.com/drugs/DB18846
    ApprovedInvestigational

    [A275338] Approved by the FDA on December 16, 2025, depemokimab is indicated as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and paediatric patients

  2. Drug

    Phenindamine

    go.drugbank.com/drugs/DB01619
    Approved

    Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells.

  3. Drug

    Anthrax vaccine

    go.drugbank.com/drugs/DB11003
    ApprovedInvestigational

    Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to Bacillus anthracis. It is subcutaneously or intramuscularly administered. It is derived f...

  4. Drug

    GPI-0100

    go.drugbank.com/drugs/DB05929
    Investigational

    The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety of vaccines, has been shown to have good overall performance characteristics on safety and efficacy

  5. Drug

    Biguanide

    go.drugbank.com/drugs/DB13100
    ApprovedInvestigationalWithdrawn

    Biguanide has been investigated for the treatment of Diabetes Mellitus.

  6. Drug

    Doxecitine

    go.drugbank.com/drugs/DB02594
    ApprovedInvestigational

    Doxecitine is currently approved and marketed as a fixed-dose combination therapy with [thymidine] (KYGEVVI).

  7. Drug

    Fasinumab

    go.drugbank.com/drugs/DB12157
    Investigational

    [A241165] NGF was first discovered in the 1950s[A241180] and was the first neurotrophic factor to be identified and biochemically characterized. … [A241190] It has since been recognized for its role in nociceptive signaling transduction and has thus become an attractive target in the treatment of chronic pain conditions.

  8. Drug

    INCB7839

    go.drugbank.com/drugs/DB05033
    Investigational

    It has shown promising clinical activity in heavily pretreated, refractory breast cancer patients.

  9. Drug

    Riferminogene pecaplasmid

    go.drugbank.com/drugs/DB06394
    Investigational

    Riferminogene pecaplasmid (non-viral fibroblast growth factor 1; NV1FGF) is a recombinant DNA plasmid in a pCOR backbone allowing expression of human FGF1.

  10. Drug

    Clascoterone

    go.drugbank.com/drugs/DB12499
    ApprovedInvestigational

    [L15621] Clascoterone is also being investigated as a novel treatment for androgenetic alopecia.[A218766] … [A218771] By competing with androgens for binding to androgen receptors, clascoterone works by blocking the androgen receptor signalling cascades that promote acne pathogenesis, such as sebaceous gland